Hengyu Bio Announces Completion of Series A+ Financing to Build a High-Standard CXO Leader in Biosafety

HENGYU BIOTECH’s rapid growth is evidenced by its agile financing pace, while the successful buildup of its talent pool has empowered the company to soar and continuously break through milestones. As a CXO platform specializing in biosafety for innovative drugs, HENGYU BIOTECH has grown its team to nearly 100 members, with over 30% holding master’s or doctoral degrees and more than 50% comprising seasoned industry professionals and engineers. Its core technical experts hail from renowned domestic and international CROs and biopharmaceutical companies, bringing profound expertise and extensive experience in project application and management. Well-versed in Chinese and foreign drug registration and quality management regulations, the team provides comprehensive biosafety-related testing and validation services throughout the entire development process of innovative biologics, therebyRigorous Testing, Multi-Regional Submissions, Agile Timelines, Rapid Response, has established stable collaborations with more than 60 renowned pharmaceutical companies both in China and abroad, earning widespread acclaim.

In 2022, with the completion of Phase II of the testing center, HENGYU BIOTECH has completed the 2.0 optimization and upgrade of its production capacity construction.BSL-2 laboratories have been established in multiple locations across China. A total of over 6,000 square meters of high-specification facilities—including testing centers, R&D centers, multiple sets of laboratories for virus clearance process validation and cell bank characterization, and independent GMP-compliant cell banking workshops—will be put into operation. These facilities can accommodate sample testing at all stages, including RCB, MCB, WCB, EOPC, and UPB. The annual capacity is sufficient to support 200 IND/BLA-stage projects, as well as release testing for hundreds of batches of mycoplasma and sterility tests. All testing methods comply with pharmacopoeial regulations and guidelines such as ChP, USP, ICH, EP, and JP.

HENGYU BIOTECH strictly adheres to GLP, GMP, CNAS, and ISO 9001 requirements, possessing a continuously improving technical system and quality assurance system,Providing Robust Support for Regulatory Submissions Across Multiple Regions. HENGYU BIOTECH has established business collaborations with over 60 innovative biopharmaceutical companies domestically and internationally, including strategic partnerships with more than ten of these firms. These collaborations span multiple fields, such as antibody and recombinant protein therapeutics, vaccines, cell and gene therapies, and stem cell-based drugs, delivering rapid-turnaround and highly compliant biosafety testing and validation services throughout the entire clinical development and marketing authorization application process for innovative pharmaceuticals.

Dr. Zhu Xiangying, Founder and CEO of HENGYU BIOTECH, stated:“We sincerely appreciate the recognition and support from our investors and partners,Amid the booming development of next-generation biotech drugs, the industry chain is facing new challenges and opportunities. Biosafety has become a top priority for innovative biologics, particularly those involving cell therapy, gene therapy, and stem cells. From manufacturing processes to quality control systems, including continuous biosafety monitoring during clinical stages, these aspects represent new challenges and critical gaps in the innovative drug industry chain that cannot be overlooked. The HENGYU BIOTECH team is committed to collaborating with new partners to transform trust into strength and resources into capability. Striving to be a trusted guardian of quality for innovative biologics, we serve global innovative pharmaceutical companies with agile delivery timelines and compliance systems and technical methodologies that meet multi-regional regulatory submission requirements.

Mr. Sun Min, General Manager of Guofang Capital, stated:“Guofang Capital has always been grounded in comprehensive insights into the industrial chain and its ecological niche advantages, focusing on empowering technology enterprises in the Yangtze River Delta. We also pay close attention to the reshaping of the industrial chain brought about by the rise of novel biologics and the high-quality investment opportunities emerging as a result. In our previous investments across the innovative biopharmaceutical industry chain, we observed that biosecurity-related CXO services represent an underserved pain point within the chain. The rapid development of HENGYU BIOTECH has further validated our strong focus on and optimism for the biosecurity sector;”We recognize HENGYU BIOTECH’s service philosophy, compliance awareness, and technical capabilities., and we are also confident that their substantial investment in the R&D of new technologies, along with their continuously deepening and expanding products and services, will be able to meet the emerging demands in the innovative drug sector. We likewise believe that Guofang Capital’s in-depth understanding of the industry chain and its multi-faceted strategic layout will empower HENGYU BIOTECH to rapidly grow into a significant force in this sector.

Mr. Xie Li, President of Haibang Investment, stated:“Haibang Capital has made multi-faceted investments in the biopharmaceutical sector and has consistently focused on high-quality CRO and CXO companies within the GCT-related industry chain,We first took notice of HENGYU BIOTECH during a Zhejiang Provincial Entrepreneurship Competition.The team’s professionalism and execution capabilities left a deep impression on us. Interviews with HENGYU BIOTECH’s clients further strengthened our confidence in its delivery capacity and quality system. We believe that with the completion of HENGYU BIOTECH’s Phase II facility, its delivery capabilities and compliance systems will reach new heights, thereby better supporting the multi-regional regulatory filing needs of innovative pharmaceutical companies. It is also poised to provide high-quality services for new drug applications in the fields of gene and cell therapy (GCT) and antibodies.

Mr. Lou Min, Chairman of Chengshu Investment, stated:“Chengshu has been deeply engaged in the biomedical supply chain for many years, focusing on identifying and supporting high-quality companies. We recognized the development potential of the HENGYU BIOTECH team as early as its inception and have supported its rapid growth through continuous empowerment. Over the past two years, HENGYU has continuously refined both its technical capabilities and quality systems, earning widespread customer recognition, achieving strong performance, and securing successful project approvals. Throughout this process, the team has also grown and strengthened.”In the face of market opportunities and challenges, this team has demonstrated its ability to navigate uncertaintyand the continuous ability to solve problems is one of HENGYU BIOTECH’s core competencies, and also the greatest source of our confidence in HENGYU BIOTECH.”

HENGYU BIOTECHZhejiang Hengyu Biotechnology Co., Ltd. (hereinafter referred to as "Hengyu Biotech") is a CXO platform founded by a top-tier scientific research team, dedicated to providing biosafety testing, related process validation, method development services, and products to global innovative pharmaceutical companies. Leveraging its BSL-2 laboratory platforms across multiple locations in China and a quality management system compliant with GLP, CNAS, GMP, and ISO 9001 standards, Hengyu Biotech offers a comprehensive suite of biosafety testing services to support the R&D and regulatory filing of biological drugs, covering the entire lifecycle from research to market launch. By upholding industry-leading rigorous testing, agile turnaround times, multi-regional filing capabilities, rapid response, systematic management, and strict data confidentiality, Hengyu Biotech strives for excellence in service quality, safeguarding the innovative R&D journeys of its global partners with reliable testing data. Hengyu Biotech is committed to becoming an industry-leading guardian of biological drug quality.

Guofang Capital is a venture capital firm dedicated to realizing technological value, with a specialized focus on hard technology. Upholding the spirit of “dancing with technology and advancing with the times,” Guofang Capital firmly believes in driving the innovation chain through the capital chain and integrating the innovation chain with the industrial chain. By strategically investing in professional VC funds, industry-chain funds, and outstanding technology enterprises, Guofang focuses on three key frontier sectors: biomedicine, artificial intelligence, and the Internet of Things (IoT). It leads broader social capital to build an ecosystem that converges resources from governments, industrial parks, finance, and industry, thereby supporting the growth of innovative enterprises and continuously enhancing the industrial chain ecosystem.

Hangzhou Haibang Venture Management Co., Ltd. (hereinafter referred to as “Haibang Investment”) is a professional investment institution specializing in equity investment and management. It was jointly established by several well-known Zhejiang-born returnee entrepreneurs and seasoned investment professionals. The management team boasts successful entrepreneurial track records and extensive investment experience. The company is committed to aggregating government, capital, industry, technology, and talent resources both domestically and internationally, striving to provide promising startups with the necessary capital and mature management expertise to facilitate their rapid growth and establish a competitive edge.

Since its establishment in 2010, Chengshu Investment has accumulated comprehensive experience across the entire lifecycle of fund operations and undergone a transformation from broad coverage to highly focused investment strategies. The Chengshu management team has participated in and witnessed the development of China’s capital markets, as well as the growth of the life sciences and consumer healthcare sectors, gaining profound insights and strong resource integration capabilities in these markets. Vision of Chengshu: To become a catalyst for the development of the life sciences and consumer healthcare industries and a trusted professional investment institution.